Mucosal immunotherapy for Alzheimer's disease with viral vectors

Hideo Hara, Makoto Inoue, Kayo Adachi, Yoshikazu Yonemitsu, Mamoru Hasegawa, Toshitaka Nabeshima, Takeshi Tabira

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Alzheimer's disease is characterized by progressive loss of cognitive function due to amyloid-β (Aβ) deposits in the central nervous system. Based on the amyloid cascade theory, many reports indicated that immunotherapy is effective for the treatment of Alzheimer's disease. We developed a mucosal immunotherapy for Alzheimer's disease via oral vaccine with recombinant adeno-associated virus (AAV) vector and nasal administration of recombinant sendaivirus vector expressing Aβ 1-43/IL-10. Oral or nasal administration of recombinant virus vector induced the long-term expression of Aβ in the epithelial cells and presented the Aβ antigen to the mucosal immune system. Antibody levels in the mouse serum were elevated after 4 weeks and the antibody inhibited the aggregation of Aβ in vitro. Immunohistochemistry of the APP transgenic mouse brain tissue showed that Aβ burdens were markedly decreased in the treated mouse compared to the control. The inflammation was not recognized in any organ including brain and kidney. Mucosal immunotherapy with viral vectors significantly cleared the Aβ depositions without inflammation and reduced the levels of Aβ in the brain homogenates of APP transgenic mice; therefore, it might be effective for the treatment of Alzheimer's disease.

Original languageEnglish
Pages (from-to)53-56
Number of pages4
JournalJapanese Journal of Neuropsychopharmacology
Volume27
Issue number2
Publication statusPublished - 01-04-2007

Fingerprint

Immunotherapy
Alzheimer Disease
Intranasal Administration
Transgenic Mice
Brain
Inflammation
Dependovirus
Synthetic Vaccines
Antibodies
Amyloid Plaques
Amyloid
Interleukin-10
Cognition
Oral Administration
Immune System
Central Nervous System
Epithelial Cells
Immunohistochemistry
Viruses
Kidney

All Science Journal Classification (ASJC) codes

  • Clinical Psychology
  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Hara, H., Inoue, M., Adachi, K., Yonemitsu, Y., Hasegawa, M., Nabeshima, T., & Tabira, T. (2007). Mucosal immunotherapy for Alzheimer's disease with viral vectors. Japanese Journal of Neuropsychopharmacology, 27(2), 53-56.
Hara, Hideo ; Inoue, Makoto ; Adachi, Kayo ; Yonemitsu, Yoshikazu ; Hasegawa, Mamoru ; Nabeshima, Toshitaka ; Tabira, Takeshi. / Mucosal immunotherapy for Alzheimer's disease with viral vectors. In: Japanese Journal of Neuropsychopharmacology. 2007 ; Vol. 27, No. 2. pp. 53-56.
@article{c6b9aa04631c46aaa360e3e8a972f12f,
title = "Mucosal immunotherapy for Alzheimer's disease with viral vectors",
abstract = "Alzheimer's disease is characterized by progressive loss of cognitive function due to amyloid-β (Aβ) deposits in the central nervous system. Based on the amyloid cascade theory, many reports indicated that immunotherapy is effective for the treatment of Alzheimer's disease. We developed a mucosal immunotherapy for Alzheimer's disease via oral vaccine with recombinant adeno-associated virus (AAV) vector and nasal administration of recombinant sendaivirus vector expressing Aβ 1-43/IL-10. Oral or nasal administration of recombinant virus vector induced the long-term expression of Aβ in the epithelial cells and presented the Aβ antigen to the mucosal immune system. Antibody levels in the mouse serum were elevated after 4 weeks and the antibody inhibited the aggregation of Aβ in vitro. Immunohistochemistry of the APP transgenic mouse brain tissue showed that Aβ burdens were markedly decreased in the treated mouse compared to the control. The inflammation was not recognized in any organ including brain and kidney. Mucosal immunotherapy with viral vectors significantly cleared the Aβ depositions without inflammation and reduced the levels of Aβ in the brain homogenates of APP transgenic mice; therefore, it might be effective for the treatment of Alzheimer's disease.",
author = "Hideo Hara and Makoto Inoue and Kayo Adachi and Yoshikazu Yonemitsu and Mamoru Hasegawa and Toshitaka Nabeshima and Takeshi Tabira",
year = "2007",
month = "4",
day = "1",
language = "English",
volume = "27",
pages = "53--56",
journal = "Japanese Journal of Psychopharmacology",
issn = "1343-4144",
publisher = "Japanese Society of Neuropsychopharmacology",
number = "2",

}

Hara, H, Inoue, M, Adachi, K, Yonemitsu, Y, Hasegawa, M, Nabeshima, T & Tabira, T 2007, 'Mucosal immunotherapy for Alzheimer's disease with viral vectors', Japanese Journal of Neuropsychopharmacology, vol. 27, no. 2, pp. 53-56.

Mucosal immunotherapy for Alzheimer's disease with viral vectors. / Hara, Hideo; Inoue, Makoto; Adachi, Kayo; Yonemitsu, Yoshikazu; Hasegawa, Mamoru; Nabeshima, Toshitaka; Tabira, Takeshi.

In: Japanese Journal of Neuropsychopharmacology, Vol. 27, No. 2, 01.04.2007, p. 53-56.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Mucosal immunotherapy for Alzheimer's disease with viral vectors

AU - Hara, Hideo

AU - Inoue, Makoto

AU - Adachi, Kayo

AU - Yonemitsu, Yoshikazu

AU - Hasegawa, Mamoru

AU - Nabeshima, Toshitaka

AU - Tabira, Takeshi

PY - 2007/4/1

Y1 - 2007/4/1

N2 - Alzheimer's disease is characterized by progressive loss of cognitive function due to amyloid-β (Aβ) deposits in the central nervous system. Based on the amyloid cascade theory, many reports indicated that immunotherapy is effective for the treatment of Alzheimer's disease. We developed a mucosal immunotherapy for Alzheimer's disease via oral vaccine with recombinant adeno-associated virus (AAV) vector and nasal administration of recombinant sendaivirus vector expressing Aβ 1-43/IL-10. Oral or nasal administration of recombinant virus vector induced the long-term expression of Aβ in the epithelial cells and presented the Aβ antigen to the mucosal immune system. Antibody levels in the mouse serum were elevated after 4 weeks and the antibody inhibited the aggregation of Aβ in vitro. Immunohistochemistry of the APP transgenic mouse brain tissue showed that Aβ burdens were markedly decreased in the treated mouse compared to the control. The inflammation was not recognized in any organ including brain and kidney. Mucosal immunotherapy with viral vectors significantly cleared the Aβ depositions without inflammation and reduced the levels of Aβ in the brain homogenates of APP transgenic mice; therefore, it might be effective for the treatment of Alzheimer's disease.

AB - Alzheimer's disease is characterized by progressive loss of cognitive function due to amyloid-β (Aβ) deposits in the central nervous system. Based on the amyloid cascade theory, many reports indicated that immunotherapy is effective for the treatment of Alzheimer's disease. We developed a mucosal immunotherapy for Alzheimer's disease via oral vaccine with recombinant adeno-associated virus (AAV) vector and nasal administration of recombinant sendaivirus vector expressing Aβ 1-43/IL-10. Oral or nasal administration of recombinant virus vector induced the long-term expression of Aβ in the epithelial cells and presented the Aβ antigen to the mucosal immune system. Antibody levels in the mouse serum were elevated after 4 weeks and the antibody inhibited the aggregation of Aβ in vitro. Immunohistochemistry of the APP transgenic mouse brain tissue showed that Aβ burdens were markedly decreased in the treated mouse compared to the control. The inflammation was not recognized in any organ including brain and kidney. Mucosal immunotherapy with viral vectors significantly cleared the Aβ depositions without inflammation and reduced the levels of Aβ in the brain homogenates of APP transgenic mice; therefore, it might be effective for the treatment of Alzheimer's disease.

UR - http://www.scopus.com/inward/record.url?scp=34249071643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249071643&partnerID=8YFLogxK

M3 - Review article

C2 - 17515110

AN - SCOPUS:34249071643

VL - 27

SP - 53

EP - 56

JO - Japanese Journal of Psychopharmacology

JF - Japanese Journal of Psychopharmacology

SN - 1343-4144

IS - 2

ER -

Hara H, Inoue M, Adachi K, Yonemitsu Y, Hasegawa M, Nabeshima T et al. Mucosal immunotherapy for Alzheimer's disease with viral vectors. Japanese Journal of Neuropsychopharmacology. 2007 Apr 1;27(2):53-56.